Beta-adrenergic blocking drugs in the treatment of hypertension

Blood Pressure

Volumn 10, Issue 5-6, 2001, Pages 366-386

  Prichard, B N C ^a   Cruickshank, J M ^a   Graham, B R ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Adverse effects; Beta 1 selectivity; Beta blockade; Co existant disease; Comparative studies; Hypertension

Indexed keywords

ACEBUTOLOL; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE; HYDROCHLOROTHIAZIDE; LABETALOL; METOPROLOL; MINOXIDIL; NADOLOL; NONSTEROID ANTIINFLAMMATORY AGENT; PINDOLOL; PLACEBO; PRACTOLOL; PRAZOSIN; PROPRANOLOL; SOTALOL; THIAZIDE DIURETIC AGENT; TIMOLOL; VERAPAMIL;

ADRENERGIC STIMULATION; AGING; ANGINA PECTORIS; ASTHMA; BED REST; CARDIOVASCULAR RISK; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SELECTIVITY; HEART FAILURE; HEART INFARCTION; HEART OUTPUT; HIGH RISK PATIENT; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LOW BIRTH WEIGHT; NEGRO; OUTCOMES RESEARCH; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIDE EFFECT; STROKE; VASCULAR RESISTANCE; CONTROLLED CLINICAL TRIAL; RISK FACTOR;

ADRENERGIC BETA-ANTAGONISTS; CONTROLLED CLINICAL TRIALS; HUMANS; HYPERTENSION; RISK FACTORS;

EID: 0035527581     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/080370501753400665     Document Type: Review

References (259)

1. Beta-blockers continue to surprise us
2. Beta-blockade and surgery
3. Hypotensive action of pronethalol in the treatment of hypertension
4. Use of propranolol in the treatment of hypertension
5. Treatment of hypertension with propranolol
6. Propranolol in hypertension: A study of long-term therapy. 1964-1970
7. Discovery of the hypotensive effect of propranolol
8. The discovery of beta-adrenoceptor blocking drugs
9. Effects of diuretic and beta-blocker therapy in the Medical Research Council Trial
10. Beta-adrenergic blockade and hypertension - 13
11. Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents
12. Comparison of bisoprolol with atenolol for systemic hypertension in four population groups (young, old, black and nonblack) using ambulatory blood pressure monitoring
13. Beta- adrenergic blockade in hypertension. Practical and theoretical implications of long-term hemodynamic variations
14. Beta-blocking drug therapy in hypertension
15. Single dose oral atenolol for urgent blood pressure reduction
16. The haemodynamic effects of beta-adrenergic blocking agents
17. Patient acceptability of propranolol and the occurence of side effects
18. Bethanidine, guanethidine and methyldopa in treatment of hypertension, a within-patient comparison
19. A within-patient comparison of bethanidine, methyldopa and propranolol in the treatment of hypertension
20. Effects of cardioselective and non-selective beta-blockade on dynamic exercise performance in mildly hypertensive men
21. Resting and exercise blood pressure with atenolol, enalapril and a low-dose combination
22. Autonomic mechanisms in haemodynamic responses to isometric exercise
23. Combined alpha- and beta-receptor inhibition in the treatment of hypertension
24. Carvedilol
25. Characterization of beta-(1)-selectivity, adrenoceptor-G(s)-protein interaction and inverse agonism of nebivolol in human myocardium
26. Nebivolol in the management of essential hypertension
27. The sixth report the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC VI)
28. Guidelines for the management of hypertension:report of the third working party of the British Hypertension Society
29. International Society of Hypertension Guidelines for the Management of Hypertension
30. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo
31. Department of Veterans Affairs Single-drug Therapy for Hypertension Study: Revised figures and new data
32. Randomised double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine and enalapril in antihypertensive treatment: Results of the HANE study
33. Treatment of Mild Hypertension Study: Final results
34. Antihypertensive efficacy of treatment regimens used in veterans administration hypertension clinics
35. Use of propranolol in conjunction with alpha-receptor blocking drugs in phaeochromocytoma
36. ICI 118551 does not redue BP in hypertensive patients responsive to atenolol and propranolol
37. Effects of the beta-2-adrenoceptor antagonist ICI 188.551 on blood pressure in hypertensive patients known to respond to beta-1-adrenoceptor antagonists
38. Compound ICI 118,551, a beta- 2-adrenoceptor antagonist, lowers blood pressure
39. Bisoprolol: A new beta-adrenoceptor blocking drug
40. Bisoprolol
41. Double-blind comparison of the cardio-selective-blockers bisoprolol and atenolol in hypertension: The Bisoprolol International Multicenter Study (BIMS)
42. A comparison of bisoprolol and atenolol in the treatment of mild to moderate hypertension
43. Does beta-1 selective agonist activity interfere with the antihypertensive efficacy of beta-1-selective blocking agents
44. Pindolol: A beta-blocker with vasodilating properties due to stimulation of vascular beta-2 adrenoceptors
45. Is the ISA of pindolol beta-2-adrenoceptor selective?
46. Ambulatory blood pressure during once-daily randomized double-blind administration of atenolol, metoprolol, pindolol and slow release propranolol
47. Carvedilol: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy
48. Clinical pharmacology of carvedilol
49. Acute and long-term hemodynamic effects of carvedilol, a combined beta-adrenoceptor blocking and precapillary vasodilating agent, in hypertensive patients
50. Effects of long-term treatment with carvedilol (BM14190) versus metoprolol on haemodynamic parameters
51. Comparison of a new vasodilating beta-blocker, carvedilol, with atenolol in the treatment of mild to moderate essential hypertension
52. A comparison of celiprolol and propranolol in the treatment of hypertension
53. Quality of life before and during antihypertensive treatment: A comparative study of celiprolol and atenolol
54. Comparison of the antihypertensive effects of celiprolol and acebutolol
55. Celiprolol stimulates endothelial nitric oxide synthase expression and improves myocardial remodelling in deoxycorticosterone acetate-salt hypertensive rats
56. Nebivolol Vasodilates Human Forearm Vasculature: Evidence for an L-Arginine/NO-Dependent Mechanism
57. Nebivolol: A third-generation beta-blocker that augments vascular nitric oxide release
58. Beta-adrenergic receptor blockade in hypertension, past, present and future
59. The use of beta-adrenergic blocking drugs in hypertension: A review
60. Lack of effect of d-propranolol on blood pressure and pulse rate in hyperensive patients
61. Beta-adrenoceptor blocking drugs
62. Renal response to propranolol treatment in hypertensive humans
63. Alternation in left ventricular filling beta-adrenergic blockade
64. Role of cardiac factors in the initial hypotensive action by beta-adrenoreceptor blocking agents
65. Sympathetic outflow to muscles during treatment of hypertension with metoprolol
66. Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases
67. Effect of alprenolol on blood pressure and plasma renin activity in hypertensive patients
68. Beta-adrenergic blockade in essential hypertension. Effects of propranolol on haemodynamic parameters and plasma renin activity
69. Dissociation between rennin and arterial pressure responses to beta-adrenergic blockade in human essential hypertension
70. Hypotensive and renin-suppressing activities of propranolol in hypertensive patients
71. Beta-adrenergic receptor blocking drugs, hypertension and plasma renin
72. Beta-adrenergic blocking agents and renin spectrum
73. Long term treatment of moderate hypertension with the beta-1-receptor blocking agent metoprolol. I. Effect on maximal working capacity, plasma catecholamines and renin, Urinary aldosterone, blood pressure and pulse conditions
74. The relationship of plasma levels of pindolol in hypertensive patients to effects on blood pressure, plasma renin and plasma noradrenaline levels
75. Effect of sotalol on haemodynamics and renin-angiotensin-aldosterone system in hypertensive patients
76. Antihypertensive and beta-adrenoceptor antagonist action of timolol
77. Beta-blockade during captopril treatment for hypertension
78. Diurnal patterns of blood pressure, heart rate and vasoactive hormones in normal man
79. Effects of atenolol and hydrochlorothiazide on blood pressure and plasma catecholamines in essential hypertension
80. Elevated plasma noradrenaline in response to beta-adrenoceptor stimulation in man
81. Antihypertensive mechanism of beta-adrenoceptor antagonism -the role of beta-2 blockade
82. Propranolol increases prostacyclin synthesis in patients with essential hypertension
83. Short-term effects of atenolol and nifedipine on atrial natriuretic peptide, plasma renin activity, and plasma aldosterone in patients with essential hypertension
84. Beta-blockade, atrial natriuretic peptide and exercise
85. The rationale for combination versus single-entity therapy in hypertension
86. Newer approaches to antihypertensive therapy:use of fixed-dose combination therapy
87. Monotherapy versus Combination Therapy as First Line Treatment of Uncomplicated Arterial Hypertension
88. The effects of cardiovascular drugs on plasma lipids and lipoproteins
89. First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension
90. A multifactorial trial design to assess combination therapy in hypertension
91. Low dose drug combination therapy:an alternative first-line approach to hypertension treatment
92. Role of nifedipine in treatment of hypertension
93. Improving the therapeutic balance between efficacy and tolerability in antihypertensive drugs - The rationale and benefits of combining felodipine and metoprolol
94. Atenolol plus nifedipine for mild to moderate systemic hypertension after fixed doses of either agent alone
95. Age and cardiovascular response adaptation. Determinants of an antihypertensive treatment concept primarily based on beta-blockers and calcium entry blockers
96. Cardiovascular responses to verapamil and propranolol in hypertensive patients
97. Treatment of essential hypertension with combined vasodilation and beta-adrenergic blockade
98. "Third drug" trial: Comparative study of antihypertensive agents added to treatment when blood pressure remains uncontrolled by a beta-blocker plus thiazide diuretic
99. The lupus syndrome induced by hydralazine:a common complication with low dose treatment
100. Prazosin and hydrallazine in the treatment of hypertension
101. The addition of prazosin to standard triple therapy in the treatment of severe hypertension
102. Comparison of nifedipine, prazosin and hydralazine added to treatment of hypertensive patients uncontrolled by thiazide diuretic plus beta-blocker
103. Prazosin: The first-dose phenomenon
104. Orthostatic hypotension due to prazosin
105. Comparison of antihypertensive and hormonal effects of captopril and propranolol at rest and during exercise
106. Acute hypotensive and rennin-stimulating actions of captopril before and after treatment with a beta-blocking drug
107. A study of the effects of lisinopril when used in addition to atenolol
108. Double-blind comparison between propranolol and bendroflumethiazide in captopril-treated resistant hypertensive patients
109. Atenolol, methyldopa, and chlorthalidone in moderate hypertension
110. Atenolol and methyldopa in the treatment of hypertension
111. Methyldopa and propranolol or practolol in moderate hypertension
112. Long term experience with the combination of clonidine and beta-adrenoceptor blocking agents in hypertension
113. Interaction of clonidine and beta-blockers
114. Clonidine and propranolol paradoxical hypertension
115. Fatal rebound hypertension after abrupt withdrawal of clonidine and propranolol
116. MRC trial of treatment of mild hypertension principal results
117. Medical Research Council trial of treatment of hypertension in older adults: Principal results
118. Atenolol versus bendroflumethiazide in middle-aged and elderly hypertensives
119. Bisoprolol versus hydrochlorothiazide plus amiloride in essential hypertension, a randomized double-blind study
120. Correction: Single-drug therapy for hypertension in men
121. Beta-1 selectivity antihypertensive effect and the frequency of stroke
122. Comparison of casual, ambulatory and self-measured blood pressure in a study of nitrendipine vs bisoprolol
123. Working ability and exercise tolerance during treatment of mild hypertension II. A comparison between atenolol and prazosin medication
124. A comparison of atenolol and long-acting trimazosin in mild to moderate essential hypertension
125. A long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate essential hypertension
126. Antihypertensive effect of doxazosin in hypertensive patients: Comparison with atenolol
127. A double-blind comparison of atenolol ('Tenormin') and methyldopa in the treatment of moderate hypertension in general practice: A multicentre study
128. Comparison of antihypertensive activity of atenolol and methyldopa at rest and during exercise
129. Prazosin and minoxidil combined with atenolol and chlorthalidone: Double-blind comparison in the treatment of severe arterial hypertension
130. A double blind comparison of moxonidine and atenolol in the management of patients with mild-to-moderate hypertension
131. Placebo-controlled trial of atenolol in treatment of pregnancy-associated hypertension
132. First year of life after the use of atenolol in pregnancy associated hypertension
133. Effectiveness of atenolol in the treatment of hypertension during pregnancy
134. Atenolol in essential hypertension during pregnancy
135. Effect of atenolol on birth weight
136. Effect of propranolol on elevated arterial blood pressure
137. Renin profiling to select antihypertensive baseline drugs. Renin inhibitors for high-renin and calcium entry blockers for low-renin patients
138. Issues, goals and guidelines for choosing first-line and combination anti-hypertensive drug therapy
139. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker and a converting enzyme inhibitor in hypertensive blacks
140. The impact of ethnicity on response to antihypertensive therapy
141. Prevalence of complications and response to different treatments of hypertension in African Americans and white Americans in the U.S
142. Use of beta-adrenergic receptor blockers in blacks
143. A comparison of celiprolol and propranolol in the treatment of hypertension in one hundred and seventy-nine subjects
144. Propranolol in the treatment of hypertension in Asians
145. Effects of beta-adrenoceptor antagonists on central haemodynamics in essential hypertension
146. Atenolol dose-finding studies
147. Experiences with beta-adrenergic blockade drugs in hypertension
148. Atenolol in the treatment of hypertension
149. Age and pathophysiology-oriented antihypertensive response to calcium antagonists
150. Treatment of hypertension in the elderly
151. Management of elderly patients with sustained hypertension
152. Diltiazem and propranolol in mild to moderate essential hypertension as monotherapy or with hydrochlorothiazide
153. Antihypertensive treatment with metoprolol or hydrochlorothiazide in patients aged 60 to 75 years. Report from a double-blind international multicenter study
154. Beta-blockers in the third millennium - When are they really indicated?
155. Effect of beta-blockade on mortality among high-risk and low-risk patients with myocardial infarction
156. Is the prognosis of heart failure improving?
157. Effect of carvedilol on survival in severe chronic heart failure
158. Diabetic patients and beta-blockers after acute myocardial infarction
159. Beta-blockers and sudden cardiac death
160. Usefulness of beta-blocker therapy in patients with non-insulin-dependant diabetes mellitus and coronary artery disease
161. Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas
162. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
163. Efficacy of atenolol and captopril in reducing risk of macrovascular and micro-vascular complications in type 2 diabetes: UKPDS 39
164. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients:results from the Swedish Trial in Old Patients with Hypertension - 2
165. Reducing perioperative myocardial infarction following vascular surgery
166. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery
167. Prophylactic atenolol reduces postoperative myocardial ischemia
168. The effect of bisoprolol on perioperative mortality and myocardial infarction in high risk patients undergoing vascular surgery
169. Bisoprolol reduces cardiac death and myocardial infarction in high-risk patients as long as 2 years after successful major vascular surgery
170. Beta-adrenergic blocking drugs. Incredibly useful, incredibly underutilized
171. The cardiovascular effect of withdrawal of beta-adrenoceptor blocking drugs
172. Esmolol and ventilatory function in cardiac patients with COPD
173. Blood pressure as a cardiovascular risk factor: Prevention and treatment
174. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy
175. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies
176. Reversal of left ventricular hypertrophy in hypertensive patients. A meta-analysis of 109 treatment studies
177. Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy
178. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension:comparison of six antihypertensive agents
179. The effects of antihypertensive therapy on left ventricular mass in elderly patients
180. Coronary heart-disease after treatment of hypertension
181. Compared incidence of first myocardial infarction in hypertensive patients under treatment containing propranolol or excluding beta-receptor blockade
182. Five year follow-up of effects of treatment of mild and moderate hypertension
183. Clinical evidence that beta-adrenoceptor blockers prevent more cardiovascular complications than other anti-hypertensive drugs
184. Low mortality from all causes, including myocardial infarction, in well-controlled hypertensives treated with a beta-blocker plus other antihypertensives
185. Beta-adrenoceptor blockade is associated with increased survival in male but not female hypertensive patients: A report from the DHSS Hypertension Care Computing Project (DHCCP)
186. Beta-blockers and primary prevention of coronary heart disease in patients with high blood pressure
187. Mild hypertension: Is there pressure to treat?
188. Stroke and coronary heart disease in mild hypertension: Risk factors and the value of treatment
189. Cardiovascular risk and risk factors in a randomised trial of treatment based on the beta-blocker oxprenolol: The International Prospective Primary Prevention Study in Hypertension (IPPPSH)
190. Beta-blockers and cardioprotection - Is there any good news from the recent trials?
191. Beta-blockers versus diuretics in hypertensive men: Main results from the HAPPHY trial
192. Primary prevention with metoprolol in patients with hypertension: Mortality results from MAPHY study
193. Reducing the risk for coronary events and stroke in hypertensive patients: Comments on present evidence
194. Primary prevention of sudden cardiovascular death in hypertensive patients. Mortality results from the MAPHY Study
195. Critical comments on recent literature: CRAAPHY about MAPHY and HAPPHY
196. MAPHY and the two arms of HAPPHY
197. Treatment of hypertension in older adults
198. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial
199. Randomised trial of treatment of hypertension in elderly patients in primary care
200. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension
201. Effect of atenolol and reserpine on selected events in the systolic hypertension in the elderly program (SHEP)
202. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)
203. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study group
204. Respiratory effects of timolol
205. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy
206. Beta-blockers, bradycardia and adverse effects
207. A randomises trial of propranolol in patients with acute myocardial infarction. II. Morbidity results
208. Adverse reactions to pindolol administration
209. Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension
210. Beta-blockers and running
211. 1-selective and nonselective beta-adrenoceptor blockade during exercise conditioning in healthy adults
212. Beta-2-adrenoceptors mediate the stimulating effect of adrenaline on active electrogenic Na-K-transport in rat soleus muscle
213. 1-selective and non-selective beta-blockade on work capacity and muscle metabolism
214. Hemodynamic and metabolic responses to exercise after adrenoceptor blockade in humans
215. Selective beta-I adrenoceptor blockade and muscle thermogenesis
216. Effect of beta-adrenoceptor blockade on thermoregulation during prolonged exercise
217. The effects of propranolol on cognitive function and quality of life: A randomized trial among patients with diastolic hypertension
218. Beta-blockers and central nervous system side effects
219. Beta-adrenoreceptor-blocking agents and the blood-brain barrier
220. A comparison of the side effects of atenolol and propranolol in the treatment of patients with hypertension
221. Withdrawal syndromes and the cessation of antihypertensive therapy
222. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS)
223. Comparison of acebutolol and propranolol in essential hypertension
224. Long-term clinical experience with atenolol - A new selective beta-1 blocker with few side-effects from the central nervous system
225. Diuretics and beta-blockers: Is there a risk for dyslipidaemia?
226. Metabolic considerations in the choice of therapy for the patient with hypertension
227. Effects of antihypertensive therapy on serum lipids
228. Association of hypertensive status and its drug treatment with lipid and haemostatic factors in middle-aged men: The PRIME study
229. A comparison of the long term effects of hydrochlorothiazide, propranolol and atenolol on carbohydrate and lipid metabolism
230. Hypertension and insulin resistance
231. Metabolic consequences of atenolol and propranolol in treatment of essential hypertension
232. Blockade of isoprenaline induced changes in plasma free fatty acids, immunoreactive insulin levels and plasma rennin activity in healthy human subjects, by propranolol, pindolol, practolol, atenolol, metoprolol and acebutolol
233. Sensitivity to insulin during treatment with atenolol and metoprolol: A randomised double-blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients
234. Beta-adrenergic receptor blockers and weight gain
235. Beta-adrenoceptor blockers, plasma-potassium, and exercise
236. Elevation of serum creatine phosphokinase during pindolol treatment
237. The place of timolol in the practice of ophthalmology
238. The effect of oral treatment with beta-blockers on the tear secretion
239. Contribution of drug treatment to symptoms of hypertensive patients
240. The effects of antihypertensive therapy on the quality of life
241. Antihypertensive therapy and quality of life: A comparison of atenolol, captopril, enalapril and propranolol
242. Quality of life on antihypertensive therapy: A randomized double-blind controlled trial of captopril and atenolol
243. Quality of life with three antihypertensive treatments: Cilazapril, atenolol and nifedipine
244. Comparison of beta-blockade and ACE inhibitors in the treatment of hypertension
245. Bisoprolol and nifedipine retard in elderly hypertensive patients: Effect on quality of life
246. Relationships of quality-of-life measures to long-term lifestyle and drug treatment in the Treatment of Mild Hypertension study
247. A randomised comparison of the effect of four antihypertensive monotherapies on the subjective quality of life in previously untreated asymptomatic patients: Field trial in general practice
248. Quality of life in hypertensive patients treated with either carvedilol or enalapril
249. Quality of life in the management of hypertension
250. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: Principle results of the HOT randomised trial
251. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial
252. Randomised double blind comparison of placebo and active treatment for old patients with isolated systolic hypertension
253. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study
254. Morbidity and mortality in patients randomised to double-blind treatment with long acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)
255. Health outcomes associated with calcium antagonists compared with other first line hypertensive therapies: A meta-analysis of randomised controlled trials
256. Effects of ACE inhibitors, calcium antagonists, and other blood pressure lowering drugs: Results of prospectively designed overviews of randomised trials